OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

OCRF Talks

2011 SGO News: MicroRNA May Help Predict Ovarian Cancer Response

Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of a small study reported here. Women with low-level expression of miR-378 after bevacizumab and chemotherapy... 

2011 SGO News: Medicare Patients Get Less Than Best Ovarian Cancer Care

Most older patients with ovarian cancer may receive care that doesn’t measure up to national standards, according to an analysis of a National Cancer Institute (NCI) database and Medicare claims data. Ten years of retrospective data from more than 8,000 women found fewer than 40% of advanced... 

Q&A with Gregory Motz, PhD.

Dr. Gregory Motz is a 2011 Ann Schreiber Program of Excellence Grantee. In this interview with OCRF’s Sarah DeFeo, Dr. Motz discusses his research, what motivated him to focus his efforts on ovarian cancer, and what it means to receive a grant from OCRF. Sarah DeFeo:  Tell me about yourself. ... 

Q&A with Ruth Perets, M.D., Ph.D., Dana Farber Cancer Institute

Dr. Ruth Perets is a 2011 Ann Schreiber Program of Excellence Grant Recipient. Her research is funded in part thanks to the support of The National Ovarian Cancer Coalition. Sarah DeFeo:  Tell me about yourself.  Do you see yourself primarily as a physician, a scientist, or both?  Ruth Perets: ... 

Interview with Jeff Boyd, PhD.

Dr. Jeff Boyd is Senior Vice President and Chief Scientific Officer of the Fox Chase Cancer Center in Philadelphia, PA.  In November 2009 he was appointed Chair of OCRF’s Scientific Advisory Committee. In this interview with OCRF’s Sarah DeFeo, Dr. Boyd shares his thoughts on the most... 

Dr. Kathryn Terry on the Genetics of Ovarian Cancer.

Kathryn Terry, ScD is an Assistant Professor of Obstetrics, Gynecology, and Reproductive Biology at the Harvard Medical School/Brigham and Women’s Hospital in Boston, MA.  She received an OCRF Liz Tilberis award in both 2006 and 2009.  She was interviewed by OCRF’s Director of Grants,... 

Q&A With Mitchell Ho, Ph.D.

Dr. Mitchell Ho is a Principal Investigator and Head of the Antibody Therapy Unit in the Laboratory of Molecular Biology at the National Cancer Institute.  He is a 2007 recipient of OCRF’s Individual Investigator Award. Sarah DeFeo:  Tell us a little about yourself and how you became interested... 

Q&A With Tian-Li Wang, PhD

Dr. Tian-Li Wang is an Assistant Professor in the Department of Obstetrics and Gynecology at the Johns Hopkins Medical Institution in Baltimore, Maryland.  She is the recipient of an OCRF Individual Investigator Award. Sarah DeFeo:  Tell us a little about yourself and how you became interested in... 

Dr. Gary Leiserowitz on the Biggest Challenge in Ovarian Cancer Research

Dr. Gary Leiserowitz is a Professor, and Chief of the Division of Gynecologic Oncology at the University of California, Davis Medical Center.  He is a 2008 recipient of OCRF’s largest and most prestigious grant, the Program Project Development Grant. Sarah DeFeo:  Dr. Leiserowitz, tell us a... 

Dr. Ernst Lengyel on Ovarian Cancer Research

Dr. Ernst Lengyel, as Associate Professor of Gynecologic Oncology at the University of Chicago, is a recipient of OCRF’s Liz Tilberis Award.  He was interviewed by OCRF’s CEO Elizabeth Howard. Elizabeth Howard:  You are studying how ovarian cancer cells metastasize through the peritoneal...